NCT00146770
MPS 1, Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.
All
Any
No
Aldurazyme, Aldurazyme, placebo
Phase 3
Interventional
45
2001-05
2015-04-03
Mobile, Alabama, United States
Atlanta, Georgia, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Toledo, Ohio, United States
Klamath Falls, Oregon, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Florianopolis, , Brazil
Florianopolis, , Brazil
Toronto, Ontario, Canada
Calgary, , Canada
Hamburg, , Germany
Hannover, , Germany
Heidelberg, , Germany
Jena, , Germany
Rome, , Italy
Rotterdam, , Netherlands
Blackpool, Lancashire, United Kingdom
Belfast, , United Kingdom
Birmingham, , United Kingdom
Bristol, , United Kingdom
Glasgow, , United Kingdom
London, , United Kingdom
Newcastle upon Tyne, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields